Company Interview / Next-generation cryo tech changing animal reproduction

Key points:

Vitrafy Life Sciences signs exclusive 12-month global agreement with IMV TechnologiesProprietary cryopreservation technology aims to reduce cell death and improve outcomesSignificant $4.8 million federal grant awarded for US human health projectsOwens sees broad global and cross-industry growth potential for Vitrafy

Vitrafy Life Sciences (ASX:VFY) has secured a significant 12-month exclusive agreement with IMV Technologies, a global leader in animal reproduction. Brent Owens states that this partnership will integrate Vitrafy’s advanced cryopreservation technology with IMV’s extensive animal reproductive services, operating across 128 countries and processing approximately 500 million individual sperm straws annually. Owens regards the agreement as game-changing due to the global reach and credibility that IMV brings to the table, enabling rapid scaling and new revenue opportunities for Vitrafy (ASX:VFY).

Owens highlights the longstanding challenges in traditional cryopreservation, such as high cell death and material damage, impacting both costs and care quality. He asserts that Vitrafy’s proprietary technology addresses these issues by improving the survival rate of preserved biomaterials, which is critical for both animal agriculture and broader scientific applications. He also foregrounds the environmental and food supply dimensions, saying that efficient cryopreservation will become increasingly vital in the animal sector.

According to Owens, the company is leveraging its innovative technology to expand beyond animal health. Vitrafy recently received a $4.8 million grant from the Australian federal government’s Industry Growth Fund to support US human health initiatives, particularly in blood preservation in collaboration with the United States Institute of Surgical Research. Owens describes this as both a financial and validation boost for Vitrafy's global ambitions.